- Home
- DAVE vs ADPT Comparison
DAVE vs ADPT Comparison
Compare DAVE & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVE | ADPT |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.5B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DAVE | ADPT |
|---|---|---|
| Price | $356.41 | $25.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $445.07 | $29.81 |
| AVG Volume (30 Days) | 222.3K | ★ 2.0M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 222.91 | 63.89 |
| EPS | ★ 4.60 | N/A |
| Revenue | ★ $554,182,000.00 | $276,976,000.00 |
| Revenue This Year | $32.00 | $5.94 |
| Revenue Next Year | $22.93 | $22.42 |
| P/E Ratio | $83.29 | ★ N/A |
| Revenue Growth | ★ 59.67 | 54.77 |
| 52 Week Low | $152.21 | $12.00 |
| 52 Week High | $458.25 | $30.74 |
Technical Indicators
Market Signals| Indicator | DAVE | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 46.87 |
| Support Level | $306.52 | $23.73 |
| Resistance Level | $386.77 | $26.51 |
| Average True Range (ATR) | 19.30 | 1.55 |
| MACD | 1.88 | -0.23 |
| Stochastic Oscillator | 48.92 | 21.68 |
Price Performance
Historical ComparisonAbout DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, short-term liquidity, fee-free banking, and financial management tools, and finding side gigs.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.